RBC Capital Maintains Outperform on Marinus Pharma, Lowers Price Target to $20
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Marinus Pharma (NASDAQ:MRNS), but lowered the price target from $21 to $20.

August 11, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained an 'Outperform' rating on Marinus Pharma but lowered the price target from $21 to $20.
The news is directly about Marinus Pharma and is likely to influence investor sentiment. While the 'Outperform' rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100